Over 30 years’ experience in oncology drug development, competitive positioning, and translational research at the global level. Hands-on experience with targeted therapeutics, monoclonal antibodies, bispecifics and other novel molecules.
Discovered the activity of Alimta in pleural mesothelioma in Phase I (which led to marketing approval), medical oversight over Ramucirumab registration studies, involvement in Olaratumab studies, and early development of several cytotoxic agents: MET, PGDGF, IGF, EGFR inhibitors.
